Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
European Medical Information Framework (EMIF)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Belgium,Netherlands,Spain,United Kingdom,Italy,Germany,France,Portugal,United Kingdom,France,Denmark,Germany,Estonia,Belgium,Sweden,Sweden,United Kingdom,United Kingdom,Finland,Germany,Germany,United Kingdom,Denmark,Denmark,Switzerland,France,Germany,Belgium,Netherlands,Germany,Germany,Belgium,Germany,Netherlands,Luxembourg,France,Netherlands
Call:  (IMI-JU-04-2011, 2011)
Start date: 2013-01-01
End date: 2018-06-30
Duration (months): 66.0
Total project cost (EUR): 55784311.0
EU funding (EUR): 24356096.0
Participants: 62
Project status: CLOSED

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aims to address this by developing a common Information Framework that enables improved access to these data sources, enhancement through linkage of the different sources and collection of additional new information. EMIF will focus on two specific research objectives in order to guide the development of the Information Framework: identification and evaluation of biomarkers i) of the risk for metabolic complications in obesity; ii) of Alzheimer’s Disease onset in the preclinical and prodromal phase, which in both cases will identify high-risk individuals for future intervention trials. To achieve this, a variety of data sources ranging from small-scale information-rich disease cohorts for biomarker discovery to large EHR data for population characterisation and biomarker validation will be utilised. An extreme phenotype approach will utilise the subpopulations at the extremes of a particular trait distribution using large-scale metabolomics and proteomics for biomarker evaluation. The development of the Information Framework will involve addressing data standards, semantic interoperability as well as ethics, data privacy, legal issues and the development of an IT platform for multi data sources access. The Information Framework will be designed to support the current research objectives, but more generally studies using human health data. The project consortium is a partnership between Academia and EFPIA and comprises a large number of world-renown experts in data access and linkage and the Metabolic and AD therapeutic areas, with many being involved in other related projects

Keywords: emif,information framework,alzheimer's disease,metabolic disorders,risk factors,biomarkers
Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Sweden,United Kingdom,Luxembourg,France,Belgium,Switzerland,France,Germany,Germany,Denmark,United Kingdom,Belgium,Belgium
Call:  (IMI-JU-04-2011, 2011)
Start date: 2012-10-01
End date: 2018-09-30
Duration (months): 72.0
Total project cost (EUR): 24244741.0
EU funding (EUR): 10309818.0
Participants: 18
Project status: CLOSED

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common platform has resulted in projects sourcing redundant KM solutions, introducing unnecessary overheads and a substantial risk to the legacy of datasets. The end result is a less than full realization of the potential of IMI to diminish bottlenecks in drug and diagnostic development. ’Delivering eTRIKS’ will address this gap by providing a sustainable, open IMI translational research informatics/KM platform – eTRIKS, and delivering associated support, expertise and services. Development will begin with transMART, an open source KM platform successfully deployed in IMI U-BIOPRED. However, eTRIKS will not end with transMART. The intent is to build a combined KM/analytics platform that can serve as a basis for continued development and ignite the formation of a cohesive informatics/KM community. Support will be provided throughout the life cycle of a translational research project, including business analysis, platform development, hosting support, data curation, and help desk. The process will be overseen by a support, governance and prioritization board. In addition, ‘Delivering eTRIKS’ will curate selected historic data sets and host in the context of active project data to aid data interpretation. A key legacy of the project will be the provision of a long-term data archive on project closure. An active community will be built to incorporate all stakeholders in ongoing and future developments. The intent is to develop a business model that enables the eTRIKS platform to persist long after the 5 years of initial IMI funding.

Keywords: services,translational research,knowledge management,transmart,analytics,big data,infrastructure,cloud computing,omics,genetics,clinical data
European Lead Factory (EUC²LID)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,Netherlands,United Kingdom,United Kingdom,Netherlands,Germany,France,Netherlands,Germany,United Kingdom,Netherlands,Germany,Denmark,United Kingdom,Belgium,Germany,Sweden,Germany,Belgium,Denmark,United Kingdom,Netherlands,Hungary
Call:  (IMI-JU-05-2012, 2012)
Start date: 2013-01-01
End date: 2018-05-31
Duration (months): 65.0
Total project cost (EUR): 196578615.0
EU funding (EUR): 79999157.0
Participants: 33
Project status: CLOSED

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provide an industry-like small molecule discovery platform to public investigators. It builds on a unique, comprehensive, high-quality compound collection contributed by EFPIA Pparticipants, i.e. the Pharma Consortium Compound Collection totaling over about 300.000 compounds. Screening of these previously safeguarded corporate compound libraries against competitor’s targets and targets from public sources may result in otherwise inaccessible valuable lead structures that could ultimately result in the development of novel treatment options for patients. Academic Participantsa or other eligible bodies (and Contributing Third Parties) will be invited to submit proposals for screening of innovative targets and to suggest the design of new and diverse chemical libraries utilizing novel concepts and strategies. The latter will fuel the generation of a Public Compound Collection that will combine with the Pharma ConsortiumEFPIA Compound Collection to generate the Joint European Compound CollectionLibrary. These public sector contributions will not only provide a constant flow of innovation, but also generate opportunities for future partnerships amongst public Public Participants and private contributors EFPIA Participants on scientific and commercial grounds. EUC2LID’s overarching goal is value creation by screening the Joint European Compound Collection Library against in pPublic and private EFPIA Ttarget Programmes. Based on the successful delivery on its objectives during the IMI funding period, the generation of the high quality Public Compound Collection provides a tangible asset allowing the transition of the European Lead Factory into a novel sustainable business model, facilitating future public-private alliances based on pre-competitive, community-based efforts in early drug research.
Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy (AETIONOMY)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Belgium,Germany,Netherlands,Germany,France,Spain,Germany,United Kingdom,Luxembourg,Sweden,Switzerland,France,Germany,Romania,Hungary
Call:  (IMI-JU-08-2012, 2012)
Start date: 2014-01-01
End date: 2018-12-31
Duration (months): 60.0
Total project cost (EUR): 17812216.0
EU funding (EUR): 7993234.0
Participants: 18
Project status: CLOSED

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerative diseases. These taxonomies will represent multi-scale structural and functional understanding of the causal mechanisms of and possible treatments in PD and AD. In particular, knowledge integration about neural substrates and their functional correlates will be generated through a pipeline that co-ordinates: I. the manual knowledge acquisition of mechanistic neurological knowledge from clinical experts, II. the semi-automated calculation of functional indices derived from clinical examination datasets, neuroradiological images and clinical and experimental investigation results, III. the large-scale acquisition of further evidence about functional relationships between knowledge created in i & ii by mining electronic health records and the literature, IV. the automated detection of significant correlations inferred from knowledge derived from steps i to iii above. To that end, AETIONOMY has assembled a seasoned consortium of expert clinicians and scientists to build upon (A) previous work within the consortium, which comprises unpublished and published work (ontologies such as ADO, the Alzheimer´s Disease Ontology, in press in “Alzheimer´s & Dementia”; disease models such as the comprehensive CellDesigner model for PD build by partner LCSB) and (B) considerable public domain resources generated by large international communities (e.g. the Neuroscience Information Framework), and (C) results from ongoing IMI projects (e.g. DDMoRe, OpenPHACTS, eTRIKS, EMIF), providing a unique combination of tools and expertise to discover the core criteria that make for a good drug target and, in so doing, classify patients according to these criteria.
E3Car -> Nanoelectronics for an energy efficient electrical car (E3CAR)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Germany,Austria,Belgium,Germany,Norway,Italy,Italy,Germany,France,Spain,Spain,Finland,France,Germany,Ireland,France,Austria,Austria,Czechia,Netherlands,Netherlands,Germany,Switzerland
Call:  (JU-ENIAC-2008-1, 2008)
Start date: 2009-02-01
End date: 2012-01-01
Duration (months): 35.0
Total project cost (EUR): 44152683.03
EU funding (EUR): 7373488.63
Participants: 33
Project status: CLOSED

The objective of the project is the development of nanoelectronics technologies, devices, circuits architectures and modules for electrical cars/vehicles and demonstration of these modules in a final systems. Emissions from road vehicles have to be reduced substantially in the future. The ultimate goal of most car manufacturers is to get to a completely electric vehicle, protecting the environment from emissions and noise, with alternative on-board energy sources (solar) and connection to the grid. In this context the project is addressing the development of highly efficient electrical vehicles, the battery control, the high-voltage components (IGBTs, high-voltage FETs) and the architectures and subsystems for the electronics of electrical vehicles. The project considers both vertical integration with the final user and equipment providers and horizontal cooperation to build a solid nanoelectronic technology base for Europe electrical car industry and establish standard designs and platforms for electrical/hybrid cars. The project will consider architectures, technologies and modules being applied to electric vehicles on systems and sub-system levels. New design and concepts are considered for power train, power conversion, power management and battery management. These systems are considered fail safe and fault tolerant and new methods and technologies for improved reliability and increased lifetime will be developed during the validation phase. In this context the power and high voltage electronics and smart miniaturized systems for power management, engine control and energy recovery systems will be specified and developed, based on the voltage / current range of needed modules. This results in research activities concerning MOS/DMOS or IGBT-Technologies to become highly energy efficient. The over all target are energy savings of 35%.

Keywords: electrical cars,power conversion,power distribution,power management
Smart Power Management in Home and Health (SMARTPM)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Germany,Germany,Belgium,Germany,Norway,Spain,Italy,Netherlands,Ireland,Germany,France,Netherlands,Germany,Germany,Sweden,Germany,France
Call:  (JU-ENIAC-2008-1, 2008)
Start date: 2009-02-01
End date: 2012-01-01
Duration (months): 35.0
Total project cost (EUR): 19827132.52
EU funding (EUR): 3311131.16
Participants: 18
Project status: CLOSED

According to studies, worldwide energy consumption is rising dramatically and will double in the next 20 years and with it CO2 emission. The consequence will be an escalating price for energy and upcoming challenges for ensuring Europe´s energy supply. Reducing Energy Consumption through energy savings can save up to 30% of Europe’s predicted energy consumption. Achieving efficient use of energy, without restricting the customer, is the political, social and technical challenge of the next decade. The high level objective of the SmartPM project is therefore to develop application-specific, efficiency-optimized semiconductor power technologies enabling actual deployment of intelligent systems in large-scale, energy-critical application fields like home and health. Applications in these fields require innovative system architectures and circuit designs, new components, efficient power electronic technologies, and innovative module, interconnect and assembly technologies. An important aspect is the support and the compatibility of upcoming legislation and regulations for efficient use of energy. The SmartPM consortium will develop semiconductor technologies and module platforms enabling (a) intelligent motor drives for highly efficient controlled engines in industrial and home applications, and (b) efficient power supplies and power management solutions that will to consume up to 25% less energy by 2012. The technologies under investigation follow the “More than Moore” path based on Si, SOI and SiC and cover different voltage ranges including low voltage (< 100V), net voltage (120V – 400V) and high voltage (>1000V). The implementation of the project results will save up to 25% of the electrical energy consumption and CO2 emission without losing performance, comfort or safety. This will reduce Europe’s dependence on energy suppliers and increase economic competitiveness by creating new market sectors and innovative applications for Europe and the world.

Keywords: innovative systems architectures and circuit designs,energy efficiancy,efficient power electronic technologies,reducing energy consumption
Models, Solutions, Methods and Tools for Energy Aware Design (END)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Italy,Italy,Italy,Germany,Spain,Greece,Spain,Belgium,Italy,Slovakia,Switzerland,Slovakia
Call:  (ENIAC-2009-1, 2009)
Start date: 2010-04-01
End date: 2013-03-01
Duration (months): 35.0
Total project cost (EUR): 13129523.0
EU funding (EUR): 2192631.0
Participants: 19
Project status: CLOSED

Energy efficiency is one of the most critical aspects of today’s information society. Reducing the energy consumption of electronic devices, circuits and systems as well as improving energy generation, conversion, storage and management capabilities are the main challenges that engineers and scientists have to face in the next decade. The ENIAC JU project END targets the development of innovative energy-aware design solutions and electronic design automation technologies for the next generation of nanoelectronics circuits and systems, and related energy generation, conversion and management systems.
Chip Architectures by Joint Associated Labs for European Diagnostics (CAJAL4EU)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Belgium,France,Netherlands,Germany,Netherlands,Hungary,Spain,Ireland,Sweden,Germany,France,Spain,France,Germany,Ireland,Ireland,Ireland,Germany,Belgium
Call:  (ENIAC-2009-1, 2009)
Start date: 2010-03-01
End date: 2013-02-01
Duration (months): 35.0
Total project cost (EUR): 22645225.0
EU funding (EUR): 3664351.0
Participants: 29
Project status: CLOSED

The main objective of the ENIAC JU project CAJAL4EU is to develop miniaturised biosensor technology platforms enabling diagnostic test manufacturers to build multi-parameter in-vitro test applications rapidly in a robust, user-friendly and cost-effective way. They will involve nanoelectronic-based transducers with chemical sensing capabilities providing the interface with the clinical samples. In contrast to other biosensor technologies, these devices will be capable of integration with low-cost CMOS nanoelectronics. The cost of a nanoelectronic biosensor can be ultra low at high volumes.
The quantitative proteomics analysis of developing embryo, endosperm and seed coat in control and Chernobyl-grown plants (PROTEOMICS OF CHERNO)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: International Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Slovakia
Call:  (FP7-PEOPLE-2007-4-3-IRG, 2007)
Start date: 2007-09-03
End date: 2011-09-02
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

With each passing year since Chernobyl accident, more questions arise about the potential for organisms adapt to radiation exposure. The explosion of one of the four reactors of Chernobyl nuclear power plant on 26 April 1986 caused worst environmental nuclear disaster in the history. It transported vast amounts of radioactive material into the atmosphere, much of which was subsequently deposited not only in the immediate vicinity of power plant in Ukraine, Belarus and Russia, but over the large parts of Europe. In this proposal, quantitative protein reference maps will be used to identify differentially expressed proteins in developing embryo, endosperm and seed coats of Chernobyl-grown plants compared to control. These reference maps will be generated during five stages of soybean and flax seed development using two-dimensional electrophoresis (2-DE) in combination with liquid chromatography connected with tandem mass spectrometry (LC-MS/MS) for protein identification.

Keywords: natural sciences,proteomics,plant development
Trans-Regional Researchers' Night in Public-Private Cooperation WonderWorld (WONDERWORLD)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Finland
Call:  (FP7-PEOPLE-2007-5-1-1-NIGHT, 2007)
Start date: 2007-06-01
End date: 2007-12-31
Duration (months): 7.0
Total project cost (EUR): 112555.0
EU funding (EUR): 100000.0
Participants: 7
Project status: CLOSED

The trans-regional (Finnish regions: Kouvola, Lappeenranta, Lahti regions) event Researchers Night has a strong aim to bring researchers into interaction with citizens and to invite all citizens and especially young people and schools to visit the open campuses that night. The Researchers’ Night intends to increase the awareness of the importance of the research, and subsequently, it is targeted to demonstrate the great importance of researchers’ work for making a better world and a better life for all. It also aims at showing, how fascinating science is. In this context especially the Marie Curie contribution to the European research will obtain an important role, but also the European academic research cooperation in general. A great diversity of technology research and humanities with a focus on partners’ main disciplines and strengths will be demonstrated to a large public in a popular way. The demonstrations will be carried out in the most different ways in laboratories and in living labs, city centers and campuses with open doors, even in IC-trains, and connected with cultural performances by local schools such as drama and music - all transmitted by video technics in open air. Excursions, debates and panels between researchers and citizens, lectures, exhibitions, presentations, round tables and entertaining discussions, a quiz “Path of Science”, researchers' bus service "Science Line" and a drawing competition will be arranged around the topic. An international on-line communication with other European universities during the event is planned. All regional players are invited to demonstrate a real research-public-private partnership and to contribute to the dialog between society and research. Additionally, two other events will take place at the same time: the 50th Anniversary of the Treaty of Rome and a commercial demonstration action called “Night of Fashion”. A visible media campaign will be arranged before and during the event.

Keywords: enhance the role of researchers f. daily life and society,encourage to researchers' career,interaction with large public,increase public understanding,attractiveness of european research area,r&d